Moderna Inc. announced over the weekend that it has dosed its first participants in each age cohort with its COVID-19 vaccine in the company’s Phase 2 study.
In a release, the biotechnology company explained that the study will evaluate the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
Some 600 people are expected to take part in the study (around 300 people between 18 and 55 years old, as well as the same number of people over the age of 55), who will be tracked for 12 months. Participants will be given a placebo, or a dose of 50 or 100 micrograms at each vaccination.
Earlier this month, the US Food and Drug Administration granted mRNA-1273 “fast track” designation.
The company’s chief scientist is Israeli-born Tal Zaks, who earlier this month told N12 that he is “not surprised that the vaccine works.”
He highlighted that the company has already been successful in developing vaccines for eight other viruses, including several specifically targeting respiratory infections.
HELP US SPREAD GOOD NEWS!
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.